(R)-2-CHLORO-1-((2-METHYLOXIRAN-2-YL)METHYL)-4-NITRO-1H-IMIDAZOLE, 95%, 250mg

(3S,4S)-tert-Butyl 3-hydroxy-4-(hydroxymethyl)pyrrolidine-1-carboxylate, 97.0%, 1g

5-cyclopropyl-1,3-oxazole-4-carboxylic acid, 95.0%, 250mg

4-(4-bromophenyl)-2-methylnicotinonitrile, 95.0%, 5g

3-(2-Bromo-4-(trifluoromethyl)phenyl)propanoic acid, 97.0%, 100mg

BenzaMide, N-[4-[(4-ethyl-1-piperazinyl)Methyl]-3-(trifluoroMethyl)phenyl]-4-Methyl-3-[[[5-(2-thienyl)-3-pyridinyl]carbonyl]aMino]-, 98%, 100mg

1H,2H,3H,4H,5H-Pyrido[4,3-b]indole-8-carboxylic acid hydrochloride, 97%, 5g

Recipiente de evaporación ROTILABO® con fondo plano, 320 ml, 10 Unidad(es)

1-(4-Fluorobenzyl)-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)urea, 98%, 1g

1,3-Dicyclohexyl-1H-benzo[d]imidazol-3-ium chloride, 98.0%, 5g

Caesium carbonate, 99.0%, 50g

N-Ethyl tadalafil, 98%, 10mg

2-METHYL-5,6,7,8-TETRAHYDROPYRIDO[4,3-D]PYRIMIDIN-4(3H)-ONE, 97.0%, 5g